| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥4.3B | ¥3.2B | +35.4% |
| Operating Income | ¥-8.6B | ¥-19.5B | +55.9% |
| Profit Before Tax | ¥-8.8B | ¥-19.6B | +55.3% |
| Net Income | ¥-8.8B | ¥-19.4B | +54.9% |
| ROE | -50.0% | -167.9% | - |
FY2025 results: Revenue ¥4.3B (YoY +35.4%), Operating Loss ¥-8.6B (YoY improvement +55.9%), Ordinary Loss ¥-9.0B (YoY -3.2%), Net Loss ¥-8.8B (YoY improvement +54.9%). The company achieved revenue growth for a second consecutive period while significantly narrowing operating losses from ¥-19.5B to ¥-8.6B. Gross profit margin remained strong at 48.3%, but high SG&A expenses of ¥6.4B (148.5% of revenue) and R&D expenses of ¥4.3B (100.2% of revenue) continued to drive operating losses. Cash position strengthened to ¥13.9B through equity financing of ¥14.2B, ensuring near-term liquidity despite negative operating cash flow of ¥-8.5B. Total assets increased to ¥21.4B with equity ratio of 81.7%, reflecting strong capitalization. The company remains in a pre-commercialization development phase with sustained R&D investment but faces critical operational challenges in achieving profitability and improving working capital efficiency.
Revenue increased ¥1.1B to ¥4.3B, representing 35.4% growth YoY. The revenue expansion reflects growth in product sales and licensing activities, though absolute revenue scale remains modest at sub-¥500M level. Gross profit reached ¥2.1B with a healthy gross margin of 48.3%, indicating strong pricing power or product mix. However, SG&A expenses totaled ¥6.4B (148.5% of revenue), while R&D expenses were ¥4.3B (100.2% of revenue), resulting in operating loss of ¥-8.6B. The operating loss improvement of ¥10.9B YoY was driven by reduced SG&A expenses (down from ¥17.2B in prior year) rather than revenue growth alone. The prior year included significant impairment losses of ¥9.6B, which did not recur in the current period, representing a major non-recurring factor in the YoY comparison. Financial costs increased from ¥0.05B to ¥0.14B, reflecting higher lease obligations and other financing costs. Equity method losses were minimal at ¥-0.01B. The gap between operating loss (¥-8.6B) and ordinary loss (¥-9.0B) of approximately ¥0.4B is attributable to net financial costs. Net loss of ¥-8.8B closely aligns with ordinary loss, with negligible tax impact (¥0.0B tax expense). Operating cash flow of ¥-8.5B represents 0.97x net income, confirming earnings quality with minimal accrual distortions. This represents a revenue up/loss narrowing pattern, where top-line growth and elimination of non-recurring impairments drove significant improvement in bottom-line losses, though the company remains deeply unprofitable operationally.
The company operates as a single reportable segment, with no separate segment disclosures provided. All operations are consolidated under pharmaceutical development and commercialization activities.
[Profitability] ROE of -60.3% reflects substantial losses relative to equity base, though this represents significant improvement from prior distressed levels following capital injection. Operating margin of -200.7% indicates the company is pre-profitability with operating expenses exceeding revenue by 2x, driven primarily by R&D intensity of 100.2% and SG&A ratio of 148.5%. Gross margin of 48.3% demonstrates strong product economics once commercialization scale is achieved. Net profit margin of -204.2% reflects comprehensive loss structure. [Cash Quality] Cash and equivalents of ¥13.9B increased ¥5.0B YoY, providing substantial liquidity buffer. Short-term debt coverage is strong given minimal financial debt (primarily lease liabilities of ¥0.3B current). Operating CF to net income ratio of 0.97x confirms earnings quality with minimal accrual distortions, though absolute operating CF remains negative at ¥-8.5B. [Investment Efficiency] Total asset turnover of 0.20x reflects low revenue generation relative to ¥21.4B asset base, typical of development-stage pharmaceutical companies with substantial cash holdings awaiting deployment. Trade receivables increased to ¥3.7B (17.4% of assets) with DSO extending to 318 days, indicating significant collection delays requiring management attention. Inventories of ¥1.1B represent 5.2% of assets with inventory turnover days of 185, suggesting slow-moving stock. [Financial Health] Equity ratio of 81.7% reflects exceptionally strong capitalization following equity financing. Current assets of ¥18.9B represent 88.1% of total assets, dominated by cash holdings. Debt-to-equity ratio of 0.22x indicates minimal leverage. Retained earnings deficit of ¥-5.2B improved substantially from ¥-32.8B through capital restructuring (likely capital reduction and offset against capital surplus). The company maintains a fortress balance sheet with negligible solvency risk but faces operational sustainability challenges given cash consumption rate.
Operating cash flow of ¥-8.5B represented 0.97x of net loss, confirming cash-backed losses with minimal working capital distortions. The operating cash outflow was driven by pre-tax loss of ¥-8.8B, partially offset by non-cash depreciation and amortization of ¥0.4B. Working capital movements were mixed, with trade receivables increasing ¥1.4B (cash outflow reflecting revenue growth but extended collection terms), inventories decreasing ¥0.2B (cash inflow from inventory reduction), and trade payables increasing ¥1.1B (cash inflow from extended supplier credit). Investing cash flow of ¥-0.8B was primarily driven by investment securities acquisition of ¥0.8B, with minimal tangible CapEx of ¥0.0B. Free cash flow of ¥-9.3B reflects combined operating and investing outflows, indicating the company is consuming capital to fund development operations. Financing cash flow of ¥14.2B was dominated by equity issuance proceeds of ¥14.6B, partially offset by lease liability payments of ¥0.3B. The substantial equity raise provided ¥5.0B net cash increase, bringing period-end cash to ¥13.9B. At current operating cash burn rate of ¥8.5B annually, the cash runway extends approximately 1.6 years, though actual runway depends on R&D spending trajectory and potential milestone receipts.
Ordinary loss of ¥-9.0B versus operating loss of ¥-8.6B reflects net non-operating expense of approximately ¥0.4B, consisting primarily of financial costs of ¥0.1B (lease interest and other finance charges) and equity method losses of ¥0.01B, partially offset by minimal financial income of ¥0.01B. Non-operating items represent 9.3% of absolute operating loss, a modest impact. The prior period included significant non-recurring factors, specifically impairment losses of ¥9.6B related to asset write-downs, which did not recur in the current period. This ¥9.6B non-recurring benefit explains the majority of the ¥10.9B operating loss improvement YoY. Adjusting for this non-recurring factor, underlying operating performance improved modestly from approximately ¥-9.9B to ¥-8.6B, representing ¥1.3B or 13% improvement driven by revenue growth outpacing operating expense increases. Operating cash flow of ¥-8.5B closely tracks net loss of ¥-8.8B with OCF/Net Income ratio of 0.97x, indicating minimal accrual-based distortions. The high cash backing of losses suggests earnings quality is appropriate for a development-stage company, with losses representing genuine cash consumption rather than accounting adjustments. The absence of material deferred tax assets recognition (¥0.0B tax benefit) reflects conservative accounting given loss carry-forward positions.
The company declared zero dividend for the fiscal year (¥0.00 per share), consistent with its pre-profitability development stage. No dividend was paid in the prior year either. Given net losses of ¥-8.8B and negative free cash flow of ¥-9.3B, dividend capacity does not exist. Payout ratio is not calculable given negative earnings. No share repurchase activity was disclosed (¥0.0B share buybacks in cash flow statement). Total shareholder return ratio is 0% as no capital was returned to shareholders. The company's investor relations materials indicate an analyst and institutional investor briefing is scheduled for February 17, 2026, where capital allocation policy and development pipeline progress are expected to be discussed.
Drug development execution risk represents the primary concern, as R&D expenses of ¥4.3B (100.2% of revenue) reflect ongoing clinical trial and regulatory investments with binary success/failure outcomes. Pipeline setbacks could result in additional impairments similar to the ¥9.6B charge in the prior year, while development delays would extend the cash consumption period and potentially necessitate dilutive financing. Working capital management risk is evidenced by days sales outstanding of 318 days and inventory turnover days of 185 days, indicating collection difficulties and slow-moving inventory. The ¥3.7B receivables balance (86% of annual revenue) suggests customer credit risk or complex milestone-based payment terms requiring close monitoring. Cash runway risk emerges from operating cash burn of ¥8.5B annually against cash holdings of ¥13.9B, implying approximately 1.6 years of runway at current burn rate. While the recent ¥14.6B equity raise provides near-term cushion, sustained losses will necessitate additional financing, creating dilution risk for existing shareholders if achieved through equity issuance or covenant/subordination risk if achieved through debt financing.
[Industry Position] (Reference - Proprietary Analysis) As a development-stage biopharmaceutical company, Solasia Pharma operates in a specialized segment characterized by high R&D intensity, pre-revenue or early revenue profiles, and capital intensity. The company's financial profile reflects typical early-stage pharmaceutical characteristics: high cash holdings (¥13.9B or 64.9% of assets), minimal tangible asset base, negative profitability metrics, and reliance on equity financing. The 81.7% equity ratio substantially exceeds industry norms where median pharmaceutical companies typically operate at 40-60% equity ratios due to greater debt capacity supported by established revenue streams. Solasia's zero-leverage capital structure (D/E 0.22x including only lease liabilities) reflects both limited debt capacity given negative cash flow and conservative treasury management prioritizing runway extension. The negative ROE of -60.3% is consistent with pre-profitability peers though actual ROE levels for loss-making entities are less meaningful than cash burn metrics. Operating margin of -200.7% and R&D intensity of 100.2% exceed median pharmaceutical industry metrics (typically 15-25% operating margins and 15-20% R&D ratios for established companies) but align with development-stage company benchmarks where R&D often equals or exceeds revenue. The company's 48.3% gross margin compares favorably to specialty pharmaceutical medians of 60-80%, suggesting either early commercialization pricing dynamics or product mix effects. Revenue growth of 35.4% YoY demonstrates strong momentum, though absolute revenue scale of ¥4.3B remains modest relative to investment requirements. The company's working capital inefficiency (DSO 318 days, DIO 185 days) exceeds industry norms and represents a key operational improvement opportunity. Overall, Solasia's financial position is best characterized as adequately capitalized for near-term development needs but requiring either significant revenue acceleration or additional financing to achieve sustainable operations. Industry comparison source: Proprietary analysis of Japanese pharmaceutical sector public company data.
Operating loss reduction of ¥10.9B YoY represents significant progress, though adjusting for prior-year non-recurring impairment of ¥9.6B reveals underlying operational improvement of only ¥1.3B, indicating the need for sustained cost discipline and revenue acceleration to achieve profitability. The company's 35.4% revenue growth across two consecutive periods demonstrates commercial traction, but absolute revenue scale of ¥4.3B remains insufficient to cover ¥10.7B in annual operating expenses (R&D ¥4.3B + SG&A ¥6.4B), implying a multi-year path to break-even requiring either 2-3x revenue scaling at current cost structure or significant operating leverage realization. Cash runway analysis shows approximately 1.6 years of liquidity at current ¥8.5B annual operating cash burn against ¥13.9B cash balance, creating a mid-2026 timeframe for either achieving materially positive cash flow, securing partnership milestone payments, or accessing additional capital markets financing. Working capital deterioration evidenced by 318-day DSO and 185-day inventory turnover represents both a risk signal regarding customer credit quality and revenue recognition practices, as well as an opportunity for ¥2-3B cash release if normalized to industry-standard 60-90 day collection cycles. The company's capital structure transformation with equity ratio improving to 81.7% and retained earnings deficit narrowing from ¥-32.8B to ¥-5.2B reflects aggressive balance sheet restructuring that has reset the capital base but also signals prior financial distress requiring investor scrutiny of legacy issues. The upcoming February 2026 analyst briefing will be critical for assessing pipeline development progress, commercial strategy for revenue acceleration, and management's plan for achieving self-sustaining operations versus reliance on continued external financing. Key monitoring metrics include quarterly DSO trends, operating expense growth relative to revenue growth, R&D milestone achievement, and cash burn trajectory relative to the 1.6-year runway baseline.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.